anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multiple sclerosis (MS) relapses are usually treated by steroids but some patients did not respond well to this treatment. In more than 40 % of MS patients experiencing relapses, residual disability accumulates in spite of steroid treatment and did not recover. Plasma exchanges (PE) are frequently used to treat the severe attacks of inflammatory demyelination in the central nervous system resistant to steroids (Tumani, 2008). This strategy has been evaluated so far only in few studies. Only one randomized controlled study has been performed (Weinshenker et al, 1999) including patients with very severe attacks of inflammatory demyelinating diseases of various origin (MS, acute transverse myelitis, acute disseminated encephalomyelitis, neuromyelitis optica), not improved after a treatment by steroids. A moderate or important improvement of incapacity was observed in 8 cases out of 19 (42.1%) after treatment by PE against 1 out of 17 (5.9%) after sham treatment. This study concerned only 12 patients having a relapse of MS. Based on this first controlled study and the experience of treatment of 42 MS patients in the department of Neurology of the University Hospital Pellegrin (CHU de Bordeaux) we designed a randomized controlled study of PE against sham PE in moderate to severe acute exacerbations of MS not responding to steroid treatment.

The purpose is to compare plasma exchanges versus sham exchanges on residual disability in MS patients with a demyelinating inflammatory episode (MS or syndrome with high risk of MS) experiencing a disabling relapse not improved after steroid treatment. The primary end-point will be evaluated one month after start of therapy. Secondary endpoints include safety and evaluation of improvement at 3 and 6 months and evaluation of safety
PROBLEM TO BE SOLVED: To provide pellets having biologically active formulations and a method of manufacturing the pellets.SOLUTION: The pellet includes a core and one or a plurality of arbitrarily chosen layers surrounding the core. The core and the layers are formed by making powder particles come into contact therewith, making them adhere to each other, and hardening them by rolling motions. The degree of densification is controlled by energy incorporated during the rolling motions. An instrument has a rotor and a chamber. The rotation of the rotor outwardly moves the pellets on the rotor during formation. Finally, the pellets come into contact with the inside wall of the chamber arranged so as to tangentially receive the outwardly moving pellets. The pellets begin to roll when coming into contact with the inwall of the chamber.
PURPOSE:To obtain a soft capsule having transparent appearance and high commercial value, free from adverse effect on human body and producible at a low cost, by including a water-soluble substance in the skin membrane and an oily liquid in the content of the same capsule. CONSTITUTION:A water-soluble substance (e.g. pyridoxine hydrochloride or chlorpheniramine maleate) is dispersed in an oily liquid (e.g. wheat embryo oil or medium-chain fatty acid triglyceride). The dispersion is enclosed with a soft capsule skin composed mainly of gelatin, glycerol, etc., and the capsule is dried to obtain the objective soft capsule. The oily liquid may contain an oil-soluble substance such as tocopherol acetate, vitamin A, vitamin D or retinol palmitate as a solute. The amount of the water-soluble substance dispersed in the oily liquid is preferably <=10wt.%, especially <=5wt.%.
Rational: Cancer sequencing (CS) promises to become the centerpiece of personalized oncology by informing on treatments targeted to each tumor's unique genetic constitution. This data can be critical to making an informed decision for disease management, though this may not be the case for all patients. CS identifies variations or differences in the DNA and/or RNA of the cells in an individual's tumor by comparison to that of his/her normal cells. These somatic variations may, on further interpretation, be identified as key drivers of carcinogenesis. Such information may predict a patient's prognosis, response to currently available treatments or prompt the development of novel therapeutics. Though CS has the potential to personalize and optimize cancer care, it may produce a vast amount of data and unique changes in the DNA/RNA that may be difficult to interpret at the present time.

Using the Integrated genomic network analysis, we could have better understanding of the underlying processes and pathways involved in tumor onset and progression. And then we could choose a specific treatment regimen and develop personalized cancer therapies
Patients will receive infusion of dexmedetomidine in the dose of 0.4 μg/kg/hr. One ml dexmedetomidine (100 μg/ml) will be diluted with 24 ml normal saline in 50 ml syringe pump to achieve dilution of 4 μg/ml.
Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
TECVAYLI can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients [see Adverse Reactions (6.1)]. 

Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines.

Monitor patients with neutropenia for signs of infection.

Withhold TECVAYLI based on severity [see Dosage and Administration (2.4)] .
Atherosclerosis is the primary underlying cause of myocardial infarction and stroke. Atherosclerotic cardiovascular disease is characterized by a chronic inflammatory reaction in medium-to-large-sized arteries, with its onset and perpetuation driven by leukocytes infiltrating the subendothelial space. Activation of endothelial cells triggered by hyperlipidaemia and lipoprotein retention in the arterial intima initiates the accumulation of pro-inflammatory leukocytes in the arterial wall, fostering the progression of atherosclerosis. This inflammatory response is coordinated by an array of soluble mediators, namely cytokines and chemokines, that amplify inflammation both locally and systemically and are complemented by tissue-specific molecules that regulate the homing, adhesion and transmigration of leukocytes. Despite abundant evidence from mouse models, only a few therapies targeting leukocytes in atherosclerosis have been assessed in humans. The major challenges for the clinical translation of these therapies include the lack of tissue specificity and insufficient selectivity of inhibition strategies. In this Review, we discuss the latest research on receptor-ligand pairs and interactors that regulate leukocyte influx into the inflamed artery wall, primarily focusing on studies that used pharmacological interventions. We also discuss mechanisms that promote the resolution of inflammation and highlight how major findings from these research areas hold promise as potential therapeutic strategies for atherosclerotic cardiovascular disease.
Pyridoxine Hydrochloride Injection, USP is a sterile solution of pyridoxine hydrochloride in Water for Injection. Each mL contains 100 mg pyridoxine hydrochloride and 0.5% chlorobutanol anhydrous (chloral deriv.). pH adjusted with sodium hydroxide if necessary (2.0 to 3.8).

Pyridoxine hydrochloride is a colorless or white crystal or a white crystalline powder. One gram dissolves in 5 mL of water. It is stable in air and is slowly affected by sunlight.

The chemical name is 2-methyl-3-hydroxy-4,5-bis (hydroxymethyl) pyridine hydrochloride.

The structural formula is:
Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer and alkylating agent.

Upon binding to CD19, loncastuximab tesirine-lpyl is internalized followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had anticancer activity in animal models of lymphoma.
Self-management describes patient's behaviours and skills to manage the physical and psychosocial impact of their illness. Empirical evidence shows that patient activation in self-management results in improved disease control and quality of life (QOL), and lower emergency department visits and hospitalizations (ED+H) and costs in other chronic conditions. Previous research conducted by the investigators of this study has shown that the quality of SMS in ambulatory care was poor and patients felt unprepared to manage treatment-related toxicities. Building on previous work, this study will evaluate a multi-faceted proactive model of care that includes: (1) training in self-management support (SMS) strategies for ambulatory nursing staff; (2) a web-based self-management education program for patients; and (3) provision of proactive, nurse-led health coaching during the first four months following the first systemic therapy administration. Using a computer-generated permuted blocks randomization scheme (permuted blocks of random size) stratified by cancer type and centre, 160 evaluable patients will be enrolled across the three participating regional cancer centres. 80 patients will be randomized to the intervention arm and 80 to the control arm. The primary objective of this study is to compare the feasibility and acceptability of the SMARTCare intervention to the active comparator (control arm). The secondary objectives are to: (1) assess the effect of the intervention on symptom control, health-related quality of life, psychological distress, patient activation and self-efficacy; (2) evaluate the effect of the intervention on service outcomes: ED+H and resource utilization; and (3) evaluate implementation outcomes: fidelity, adherence and adoption. In addition, patients randomized to the intervention arm will be asked to participate in a sub-study interview at the end of the study to gain further knowledge about the SMARTCare intervention components from the patient's perspective.
Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
OBJECTIVE: To compare the safety, clinical outcomes, and radiological results of anterior cervical discectomy and fusion (ACDF) with zero-profile anchored spacer (ZPAS) versus plate and cage (PC) for 3-level contiguous cervical degenerative disease.
METHODS: The study was registered at PROSPERO (CRD42024512706). The Web of Science core collection, PubMed, and Embase were searched up to February 12, 2024. Review Manager 5.3 was used. The relative risk (RR) and 95% confidence interval were evaluated for dichotomous data. Continuous data were assessed using the mean difference and 95% confidence interval.
RESULTS: Nine studies comparing ACDF with ZPAS versus PC for 3-level contiguous cervical degenerative disease were included. The intraoperative blood loss and operation time in ZPAS were significantly less than those in PC. The subsidence rate, loss of cervical alignment, fusion segmental height, and intervertebral disc height were significantly greater in ZPAS than in PC. The cervical alignment and dysphagia rate within 6 months were significantly lower in ZPAS than in PC. The ASD of ZPAS was significantly lower than that of PC according to the sensitivity analysis when 1 study was excluded. No significant differences were identified in the other aspects.
CONCLUSIONS: Both ACDF with ZPAS and PC were safe and effective procedures. PC was associated with increased surgical trauma. The ZPAS could better decrease the incidence of ASD and dysphagia. ZPAS was also accompanied by high subsidence rate and poor cervical alignment.
FIELD: medicine; pharmaceuticals; food industry.SUBSTANCE: invention refers to pharmaceutical and food industry, namely to application of Cistanche tubulosa extract for production of product for prevention, retardation or treatment of eye diseases caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light. Use of the extract of Cistanche tubulosa for preparing a drug for preventing, slowing or treating eye diseases caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light, wherein the extract of Cistanche tubulosa contains a component selected from a group consisting of echinacid, actezide, isoachtoiside, tubulozide A or a combination thereof. Use of a component of a Cistanche tubulosa extract selected from a group comprising echinACoside, actoteside, isoachtoside, tubuloside A or a combination thereof, for preparing a medicinal agent for preventing, slowing or treating eye diseases caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light. Application of Cistanche tubulosa extract for food product preparation for protection of eye cells from damage caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light, wherein Cistanche tubulosa extract contains a component selected from the group consisting of echinacoside, actezide, isoachtoiside, tubuloside A or a combination thereof. Use of a component of a Cistanche tubulosa extract selected from a group comprising echinACoside, actoteside, isoachtoside, tubuloside A or a combination thereof, for preparing a food product for protecting the eye cells from damage caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light. Use of the extract of Cistanche tubulosa for preparing a medicinal agent for protecting the eye cells from damage caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light, wherein the extract of Cistanche tubulosa contains a component selected from a group consisting of echinacoside, actoteside, isoachtoiside, tubuloside A or a combination thereof. Use of a component of a Cistanche tubulosa extract selected from a group comprising echinACoside, actoteside, isoachtoside, tubuloside A or a combination thereof, for preparing a medicinal agent for protecting the eye cells from damage caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light.EFFECT: agents described above are effective for protecting eye cells from damage caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light, or for preventing, slowing or treating eye diseases caused by oxidative stress induced by tert-butyl hydroperoxide (t-BHP), ischemia or blue light.19 cl, 25 dwg, 3 tbl, 2 ex
AIMS: A three-dimensional electroanatomic mapping system-guided transseptal puncture (3D-TSP), without fluoroscopy or echocardiography, has been only minimally reported. Indications for 3D-TSP remain unclear. Against this background, this study aims to establish a precise technique and create a workflow for validating and selecting eligible patients for fluoroless 3D-TSP.
METHODS AND RESULTS: We developed a new methodology for 3D-TSP based on a unipolar electrogram derived from a transseptal needle tip (UEGM tip) in 102 patients (the derivation cohort) with intracardiac echocardiography (ICE) from March 2018 to February 2019. The apparent current of injury (COI) was recorded at the muscular limbus of the foramen ovalis (FO) on the UEGM tip (sinus rhythm: 2.57 ± 0.95 mV, atrial fibrillation: 1.92 ± 0.77 mV), which then disappeared or significantly reduced at the central FO. Changes in the COI, serving as a major criterion to establish a 3D-TSP workflow, proved to be the most valuable indicator for identifying the FO in 99% (101/102) of patients compared with three previous techniques (three minor criteria) of reduction in atrial unipolar or bipolar potential and FO protrusion. A total of 99.9% (1042/1043) patients in the validation cohort underwent successful 3D-TSP through the workflow from March 2019 to July 2023. Intracardiac echocardiography guidance was required for 6.6% (69/1042) of patients. All four criteria were met in 740 patients, resulting in a 100% pure fluoroless 3D-TSP success rate.
CONCLUSION: In most patients, fluoroless 3D-TSP was successfully achieved using changes in the COI on the UEGM tip. Patients who met all four criteria were considered suitable for 3D-TSP, while those who met none required ICE guidance.
The invention belongs to a traditional Chinese medicine and discloses a traditional Chinese medicine for treating hyperthyroidism. The traditional Chinese medicine for treating hyperthyroidism comprises 10-20g of root of straight ladybell, 10-20g of tuber of dwarf lilyturf, 10-20g of pollen, 10-20g of Chinese angelica, 3-9g of raw licorice and 2-4g of white mustard seed. The above materials are decocted in clear water and the decoction is taken twice every day. In a treatment course, 5 doses of the traditional Chinese medicines are used continuously. Through use of the traditional Chinese medicine for 3-5 days, symptoms are reduced and hyperthyroidism can be cured after 2 months. The traditional Chinese medicine is designed according to the traditional Chinese medicine differentiation theory, has a simple formula, utilizes the easily acquired raw materials, has a low cost and high curative effects and no toxic or side effect, and can regulate the human body to a normal state.
PURPOSE:To obtain a composite, capable of remarkably improving the redispersibility in water and dispersible therein with a low shearing force and providing a stable colloid without sandiness by blending fine cellulose with water-soluble natural gums, water-soluble synthetic gums and a hydrophilic substance according to a specific composition. CONSTITUTION:This composite is a dry composite, having a composition composed of water-soluble natural gums and water-soluble synthetic gums in the total amount (X pts.wt.) of 0.5-40 pts.wt. and a hydrophilic substance in an amount (Y pts.wt.) of 0-100 pts.wt. based on 100 pts.wt. fine cellulose and satisfying the formula 2X+Y>=10. When redispersing the composite in water, the content of particles having >=10mum size is <=40% and the colloid fraction is >=65%. The average particle diameter of the aqueous dispersion is <=8mum and the content of particles having >=10mum is especially preferably <=5%. The redispersibility of the composite is remarkably improved by combining the water-soluble natural gums with the synthetic gums and the ratio of the natural gums to the synthetic gums is preferably within the range of (19:1) to (1:4), especially (19:1) to (1:1).
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ciprofloxacin tablets for a condition for which it is not prescribed. Do not give ciprofloxacin tablets to other people, even if they have the same symptoms that you have. They may harm them. 

This Medication Guide summarizes the most important information about ciprofloxacin tablets. If you would like more information about ciprofloxacin tablets, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about ciprofloxacin tablets that is written for healthcare professionals. For more information call 1-866-850-2876.
Retroviral sequences were characterised by RT-PCR with gag and env primers on RNA from RT-positive retroviral particles produced by multiple sclerosis (MS) derived B-lymphoblastoid cell lines. Sequence variants with high homology to the potentially functional subgroup RGH of the human endogenous retrovirus RTVL-H/HERV-H family were found. The same sequences were also specifically found in the particulate fraction of a series of MS patient plasma samples and were absent in controls. South-Western blots demonstrated the presence of a nucleic acid binding protein, corresponding in size and function to the nucleocapsid protein, Gag NC, of other retroviruses. Indications for transmission of the retrovirus to mononuclear blood cells from healthy human individuals and non-human animals were found. Cell cultures derived from peripheral blood from MS patients contained 5-15 % CD3+ T-cells and a specific splice variant of the env sequence comprising a region of the pol region was identified in such cultures.
The invention discloses a lyase LysPd424 with an ultra-broad spectrum cleavage activity and application thereof. The amino acid sequence of the lyase LysPd424 is shown as SEQ ID NO.1, and the nucleotide sequence is shown as SEQ ID NO. 2. This set of sequences is from the actinomycetes with actinomycetes genome. Experiments prove that the lyase LysPd424 has good cracking effect on pathogenic bacteria related to periodontitis diseases, such as porphyromonas gingivalis, fusobacterium nucleatum, actinobacillus actinomyces, and the like in vitro, has good cracking effect on enterococcus faecalis, streptococcus mutans, acinetobacter baumannii and pseudomonas aeruginosa, and can kill gram-positive bacteria and gram-negative bacteria in an ultra-broad spectrum. The lyase LysPd424 can be subjected to soluble expression in escherichia coli, has high enzyme yield, and has good application prospect in the research and development of anti-infective drugs.